Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B

World Journal of Gastroenterology

Volumn 13, Issue 30, 2007, Pages 4096-4099

  Del Poggio, Paolo ^a   Zaccanelli, Maurizio ^a   Oggionni, Maria ^a   Colombo, Silvia ^a   Jamoletti, Carlo ^a   Puhalo, Vesna ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Adefovir; Chronic hepatitis B; Low income countries; Nucleotide analogues; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALCOHOL; CANRENOIC ACID; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NADOLOL; NUCLEOTIDE; TENOFOVIR DISOPROXIL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MALE; MONOTHERAPY; OPEN STUDY; POLYMERASE CHAIN REACTION; VIREMIA; VIRUS RESISTANCE;

EID: 34548278800     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i30.4096     Document Type: Article

References (24)

1. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, Trepo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398
2. Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-2477
3. Wong SN, Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology 2006; 44: 309-313
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
5. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-1425
6. van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-325
7. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43: 904-910
8. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139: 313-320
9. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu. B, Toole JJ, Cheng AK. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201
10. Antoniou T, Raboud J, Chirhin S, Yoong D, Govan V, Gough K, Rachlis A, Loutfy M. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6: 284-290
11. Danta M, Dusheiko G. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int J Clin Pract 2004; 58: 877-886
12. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734
13. van Bommel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology 2005; 42: 239-340
14. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612
15. Qi X. Anti HBV efficacy and intracellular metabolism of TDF (abstract). J Hepatol 2005; 42 (suppl 2): 32
16. Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 2005; 39: 406-411
17. Mohammad Alizadeh AH, Ranjbar M, Karimi B, Hatami S. Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran. World J Gastroenterol 2006; 12: 4203-4205
18. Aggarwal R, Ghoshal UC, Naik SR. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J India 2002; 15: 320-327
19. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821-831
20. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-xiv, 1-183
21. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61
22. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005; 12: 364-372
23. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29: 510-517
24. World Health Organization. ARV treatment guidelines and technical and operational recommendations for ART. Available from: URL: http://www.who.int/3by5/publications/briefs/oms09arvguidelines.pdf